OptiNose, Inc. (NASDAQ:OPTN) Stock Holdings Lessened by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its position in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 333,333 shares of the company's stock after selling 4,666,667 shares during the period. D. E. Shaw & Co. Inc. owned approximately 3.31% of OptiNose worth $2,227,000 at the end of the most recent reporting period.

Separately, Acorn Capital Advisors LLC acquired a new stake in OptiNose during the 4th quarter valued at $2,824,000. 85.60% of the stock is owned by institutional investors and hedge funds.

OptiNose Price Performance

OPTN stock remained flat at $9.60 during mid-day trading on Friday. The company has a market capitalization of $97.22 million, a P/E ratio of -2.29 and a beta of -0.88. OptiNose, Inc. has a twelve month low of $4.82 and a twelve month high of $20.03. The company has a fifty day simple moving average of $9.13 and a 200 day simple moving average of $7.44.

OptiNose (NASDAQ:OPTN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.27). The business had revenue of $18.51 million for the quarter, compared to the consensus estimate of $17.70 million. As a group, research analysts anticipate that OptiNose, Inc. will post -3.22 earnings per share for the current fiscal year.

Insider Transactions at OptiNose

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the transaction, the chief executive officer now directly owns 126,931 shares in the company, valued at approximately $671,464.99. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 8,213 shares of company stock worth $43,643. 2.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on OPTN shares. Piper Sandler reaffirmed a "neutral" rating and set a $9.00 price target (down from $15.00) on shares of OptiNose in a report on Friday, March 21st. HC Wainwright reissued a "neutral" rating and set a $9.00 price objective on shares of OptiNose in a report on Monday. Finally, Lake Street Capital lowered shares of OptiNose from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $17.00 to $9.00 in a report on Thursday, March 20th.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.